<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421148</url>
  </required_header>
  <id_info>
    <org_study_id>P05961</org_study_id>
    <secondary_id>2004-003819-23</secondary_id>
    <secondary_id>19.4.306</secondary_id>
    <secondary_id>MK-8616-034</secondary_id>
    <secondary_id>P05961</secondary_id>
    <nct_id>NCT00421148</nct_id>
  </id_info>
  <brief_title>Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)</brief_title>
  <official_title>A Multi-Center, Randomized, Parallel Dose-Finding, Safety Assessor-Blinded Trial to Explore the Efficacy, Safety and Pharmacokinetics of Four Doses of Org 25969 and Placebo in Pediatric and Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  to explore the dose-response relation of sugammadex (Org 25969, MK-8616, SCH 900616)
           given as a reversal agent at reappearance of T2 after 0.6 mg.kg-1 rocuronium in
           pediatric and adult participants

        -  to explore the pharmacokinetics (PK) of sugammadex in pediatric and adult participants,
           and to evaluate the safety of sugammadex in pediatric and adult participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2005</start_date>
  <completion_date type="Actual">June 2, 2006</completion_date>
  <primary_completion_date type="Actual">May 31, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.9</measure>
    <time_frame>From start of sugammadex or palcebo administration to recovery of T4/T1 ratio to 0.9 (ranging from ~0.5 minutes to ~30 minutes from sugammadex or placebo administration)</time_frame>
    <description>Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds &amp; assessing twitch response at the adductor pollicis muscle. T1 &amp; T4 refer to the magnitudes (heights) of the first &amp; fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached ≥0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.7</measure>
    <time_frame>From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.7 (ranging from ~0.4 minutes to ~20 minutes from sugammadex or placebo administration)</time_frame>
    <description>Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds &amp; assessing twitch response at the adductor pollicis muscle. T1 &amp; T4 refer to the magnitudes (heights) of the first &amp; fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.8</measure>
    <time_frame>From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.8 (ranging from ~0.5 minutes to ~25 minutes from sugammadex or placebo administration)</time_frame>
    <description>Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds &amp; assessing twitch response at the adductor pollicis muscle. T1 &amp; T4 refer to the magnitudes (heights) of the first &amp; fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Sugammadex 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are to receive an intravenous (IV) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex is to be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex is to be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex is to be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex is to be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single 3-mL bolus dose of placebo (sodium chloride 0.9% solution) is to be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 0.5 mg/kg</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Sugammadex 0.5 mg/kg</arm_group_label>
    <other_name>Org 25969</other_name>
    <other_name>MK-8616</other_name>
    <other_name>SCH 900616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 1 mg/kg</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Sugammadex 1 mg/kg</arm_group_label>
    <other_name>Org 25969</other_name>
    <other_name>MK-8616</other_name>
    <other_name>SCH 900616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 2 mg/kg</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Sugammadex 2 mg/kg</arm_group_label>
    <other_name>Org 25969</other_name>
    <other_name>MK-8616</other_name>
    <other_name>SCH 900616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 4 mg/kg</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Sugammadex 4 mg/kg</arm_group_label>
    <other_name>Org 25969</other_name>
    <other_name>MK-8616</other_name>
    <other_name>SCH 900616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sodium chloride 0.9% solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium bromide</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sugammadex 0.5 mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 1 mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 2 mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 4 mg/kg</arm_group_label>
    <other_name>ESMERON®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) class 1 - 2, between the ages of 28 days
             and 65 years inclusive, and between the ages of 2 and 65 years inclusive for Germany
             and between the ages of 6 and 65 years inclusive for Finland

          -  Scheduled for general anesthesia with an anticipated duration of anesthesia of at
             least 60 minutes, without further need for muscle relaxation other than one single
             dose of 0.6 mg/kg rocuronium

          -  Scheduled for surgical procedures in the supine position

          -  Participants who, and/or whose parent(s) or legal guardian(s) have given written
             informed consent [or appropriate assent, if applicable]

        Exclusion Criteria:

          -  Known or suspected neuromuscular disorders impairing neuromuscular blockade (NMB)
             and/or significant renal dysfunction, in Germany creatinine and blood urea nitrogen
             outside local reference ranges

          -  Known or suspected to have a (family) history of malignant hyperthermia

          -  Known or suspected to have an allergy to narcotics, muscle relaxants or other
             medication used during general anesthesia

          -  Use of medication expected to interfere with the rocuronium given in this trial, based
             on the dose and the time of administration

          -  Pregnancy

          -  Childbearing potential not using any of the following methods of birth control: condom
             or diaphragm with spermicide, vasectomized partner (&gt;6 months), intrauterine device
             (IUD), abstinence

          -  Breast-feeding

          -  Prior participation in any study with Org 25969 (sugammadex)

          -  Participation in another clinical trial, not pre-approved by NV Organon, within 30
             days of entering into study 19.4.306 (MK-8616-034, P05961)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </removed_countries>
  <results_reference>
    <citation>Plaud B, Meretoja O, Hofmockel R, Raft J, Stoddart PA, van Kuijk JH, Hermens Y, Mirakhur RK. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology. 2009 Feb;110(2):284-94. doi: 10.1097/ALN.0b013e318194caaa.</citation>
    <PMID>19194156</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 8, 2007</study_first_submitted>
  <study_first_submitted_qc>January 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <results_first_submitted>August 8, 2018</results_first_submitted>
  <results_first_submitted_qc>August 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2019</results_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited participants were stratified between Infants (28 days-23 months of age), Children (2-11 years of age), Adolescents (12-17 years of age) and Adults (18-65 years of age). For Participant Flow, participants are included in the treatment group to which they were randomized.</recruitment_details>
      <pre_assignment_details>One adolescent participant was inadvertently randomized to Children: Sugammadex 4 mg/kg, but was included in Adolescents: Sugammadex 4 mg/kg for safety analyses. One participant was randomized to Adolescents: Sugammadex 0.5 mg/kg, but received sugammadex 5.0 mg/kg &amp; was included in the Adolescents: Sugammadex 4 mg/kg for safety analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Infants: Placebo</title>
          <description>Infant participants received an intravenous (IV) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
        </group>
        <group group_id="P2">
          <title>Infants: Sugammadex 0.5 mg/kg</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P3">
          <title>Infants: Sugammadex 1 mg/kg</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P4">
          <title>Infants: Sugammadex 2 mg/kg</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P5">
          <title>Infants: Sugammadex 4 mg/kg</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P6">
          <title>Children: Placebo</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
        </group>
        <group group_id="P7">
          <title>Children: Sugammadex 0.5 mg/kg</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P8">
          <title>Children: Sugammadex 1 mg/kg</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered</description>
        </group>
        <group group_id="P9">
          <title>Children: Sugammadex 2 mg/kg</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P10">
          <title>Children: Sugammadex 4 mg/kg</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P11">
          <title>Adolescents: Placebo</title>
          <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
        </group>
        <group group_id="P12">
          <title>Adolescents: Sugammadex 0.5 mg/kg</title>
          <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P13">
          <title>Adolescents: Sugammadex 1 mg/kg</title>
          <description>Adolescents participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P14">
          <title>Adolescents: Sugammadex 2 mg/kg</title>
          <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P15">
          <title>Adolescents: Sugammadex 4 mg/kg</title>
          <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P16">
          <title>Adults: Placebo</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
        </group>
        <group group_id="P17">
          <title>Adults: Sugammadex 0.5 mg/kg</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P18">
          <title>Adults: Sugammadex 1 mg/kg</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P19">
          <title>Adults: Sugammadex 2 mg/kg</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="P20">
          <title>Adults: Sugammadex 4 mg/kg</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="6"/>
                <participants group_id="P18" count="6"/>
                <participants group_id="P19" count="6"/>
                <participants group_id="P20" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4">1 additional participant discontinued prior to receiving study treatment</participants>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="5">Includes 1 participant who was inadvertently randomized to group but was an adolescent</participants>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6">Includes 1 participant who was inadvertently randomized to group but received 5 mg/kg sugammadex</participants>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="6"/>
                <participants group_id="P18" count="5">1 additional participant discontinued prior to receiving study treatment</participants>
                <participants group_id="P19" count="5">1 additional participant discontinued prior to receiving study treatment</participants>
                <participants group_id="P20" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="6"/>
                <participants group_id="P18" count="4"/>
                <participants group_id="P19" count="5"/>
                <participants group_id="P20" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="2"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The All-Participants-Treated (APT) population consisted of all treated participants. Three additional participants withdrew from the study before receiving treatment &amp; were not included in the Baseline Analysis Population. For the APT population, participants with incorrect randomization are included under the actual dose group they received.</population>
      <group_list>
        <group group_id="B1">
          <title>Infants: Placebo</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
        </group>
        <group group_id="B2">
          <title>Infants: Sugammadex 0.5 mg/kg</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B3">
          <title>Infants: Sugammadex 1 mg/kg</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B4">
          <title>Infants: Sugammadex 2 mg/kg</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B5">
          <title>Children: Placebo</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
        </group>
        <group group_id="B6">
          <title>Children: Sugammadex 0.5 mg/kg</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B7">
          <title>Children: Sugammadex 1 mg/kg</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered</description>
        </group>
        <group group_id="B8">
          <title>Children: Sugammadex 2 mg/kg</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B9">
          <title>Children: Sugammadex 4 mg/kg</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B10">
          <title>Adolescents: Placebo</title>
          <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
        </group>
        <group group_id="B11">
          <title>Adolescents: Sugammadex 0.5 mg/kg</title>
          <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B12">
          <title>Adolescents: Sugammadex 1 mg/kg</title>
          <description>Adolescents participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B13">
          <title>Adolescents: Sugammadex 2 mg/kg</title>
          <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B14">
          <title>Adolescents: Sugammadex 4 mg/kg</title>
          <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B15">
          <title>Adults: Placebo</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
        </group>
        <group group_id="B16">
          <title>Adults: Sugammadex 0.5 mg/kg</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B17">
          <title>Adults: Sugammadex 1 mg/kg</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B18">
          <title>Adults: Sugammadex 2 mg/kg</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B19">
          <title>Adults: Sugammadex 4 mg/kg</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B20">
          <title>Infants: Sugammadex 4 mg/kg</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="B21">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="5"/>
            <count group_id="B8" value="5"/>
            <count group_id="B9" value="4"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="5"/>
            <count group_id="B12" value="6"/>
            <count group_id="B13" value="6"/>
            <count group_id="B14" value="8"/>
            <count group_id="B15" value="6"/>
            <count group_id="B16" value="6"/>
            <count group_id="B17" value="5"/>
            <count group_id="B18" value="5"/>
            <count group_id="B19" value="6"/>
            <count group_id="B20" value="1"/>
            <count group_id="B21" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" spread="0"/>
                    <measurement group_id="B2" value="1" spread="0"/>
                    <measurement group_id="B3" value="1" spread="0"/>
                    <measurement group_id="B4" value="0" spread="NA">NA=Not calculated on 1 participant</measurement>
                    <measurement group_id="B5" value="9" spread="1"/>
                    <measurement group_id="B6" value="9" spread="3"/>
                    <measurement group_id="B7" value="8" spread="2"/>
                    <measurement group_id="B8" value="9" spread="2"/>
                    <measurement group_id="B9" value="6" spread="3"/>
                    <measurement group_id="B10" value="15" spread="2"/>
                    <measurement group_id="B11" value="14" spread="1"/>
                    <measurement group_id="B12" value="15" spread="2"/>
                    <measurement group_id="B13" value="14" spread="0"/>
                    <measurement group_id="B14" value="14" spread="2"/>
                    <measurement group_id="B15" value="49" spread="12"/>
                    <measurement group_id="B16" value="41" spread="17"/>
                    <measurement group_id="B17" value="37" spread="8"/>
                    <measurement group_id="B18" value="38" spread="10"/>
                    <measurement group_id="B19" value="38" spread="14"/>
                    <measurement group_id="B20" value="1" spread="NA">NA=Not calculated on 1 participant</measurement>
                    <measurement group_id="B21" value="19.8" spread="16.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="2"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="4"/>
                    <measurement group_id="B17" value="3"/>
                    <measurement group_id="B18" value="4"/>
                    <measurement group_id="B19" value="4"/>
                    <measurement group_id="B20" value="1"/>
                    <measurement group_id="B21" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.9</title>
        <description>Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds &amp; assessing twitch response at the adductor pollicis muscle. T1 &amp; T4 refer to the magnitudes (heights) of the first &amp; fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached ≥0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB.</description>
        <time_frame>From start of sugammadex or palcebo administration to recovery of T4/T1 ratio to 0.9 (ranging from ~0.5 minutes to ~30 minutes from sugammadex or placebo administration)</time_frame>
        <population>The Per Protocol (PP) population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo) &amp; had ≥1 post-baseline efficacy measurement for this outcome measure &amp; had no protocol violations. For efficacy, participants with incorrect randomization were included under the planned dose group.</population>
        <group_list>
          <group group_id="O1">
            <title>Infants: Placebo</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
          </group>
          <group group_id="O2">
            <title>Infants: Sugammadex 0.5 mg/kg</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O3">
            <title>Infants: Sugammadex 1 mg/kg</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O4">
            <title>Infants: Sugammadex 2 mg/kg</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O5">
            <title>Children: Placebo</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
          </group>
          <group group_id="O6">
            <title>Children: Sugammadex 0.5 mg/kg</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O7">
            <title>Children: Sugammadex 1 mg/kg</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered</description>
          </group>
          <group group_id="O8">
            <title>Children: Sugammadex 2 mg/kg</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O9">
            <title>Children: Sugammadex 4 mg/kg</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O10">
            <title>Adolescents: Placebo</title>
            <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
          </group>
          <group group_id="O11">
            <title>Adolescents: Sugammadex 0.5 mg/kg</title>
            <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O12">
            <title>Adolescents: Sugammadex 1 mg/kg</title>
            <description>Adolescents participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O13">
            <title>Adolescents: Sugammadex 2 mg/kg</title>
            <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O14">
            <title>Adolescents: Sugammadex 4 mg/kg</title>
            <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O15">
            <title>Adults: Placebo</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
          </group>
          <group group_id="O16">
            <title>Adults: Sugammadex 0.5 mg/kg</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O17">
            <title>Adults: Sugammadex 1 mg/kg</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O18">
            <title>Adults: Sugammadex 2 mg/kg</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O19">
            <title>Adults: Sugammadex 4 mg/kg</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O20">
            <title>Infants: Sugammadex 4 mg/kg</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.9</title>
          <description>Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds &amp; assessing twitch response at the adductor pollicis muscle. T1 &amp; T4 refer to the magnitudes (heights) of the first &amp; fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached ≥0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB.</description>
          <population>The Per Protocol (PP) population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo) &amp; had ≥1 post-baseline efficacy measurement for this outcome measure &amp; had no protocol violations. For efficacy, participants with incorrect randomization were included under the planned dose group.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="5"/>
                <count group_id="O17" value="5"/>
                <count group_id="O18" value="5"/>
                <count group_id="O19" value="5"/>
                <count group_id="O20" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.98" spread="11.30"/>
                    <measurement group_id="O2" value="3.72" spread="0.63"/>
                    <measurement group_id="O3" value="2.42" spread="0.70"/>
                    <measurement group_id="O4" value="0.58" spread="NA">NA=Not calculated on 1 participant</measurement>
                    <measurement group_id="O5" value="19.57" spread="10.97"/>
                    <measurement group_id="O6" value="5.22" spread="3.50"/>
                    <measurement group_id="O7" value="3.95" spread="3.23"/>
                    <measurement group_id="O8" value="1.20" spread="0.35"/>
                    <measurement group_id="O9" value="1.57" spread="1.90"/>
                    <measurement group_id="O10" value="22.77" spread="13.10"/>
                    <measurement group_id="O11" value="11.97" spread="17.65"/>
                    <measurement group_id="O12" value="1.77" spread="0.37"/>
                    <measurement group_id="O13" value="1.87" spread="1.70"/>
                    <measurement group_id="O14" value="1.08" spread="0.25"/>
                    <measurement group_id="O15" value="29.48" spread="8.43"/>
                    <measurement group_id="O16" value="3.77" spread="1.12"/>
                    <measurement group_id="O17" value="1.62" spread="0.30"/>
                    <measurement group_id="O18" value="1.27" spread="0.27"/>
                    <measurement group_id="O19" value="1.37" spread="0.38"/>
                    <measurement group_id="O20" value="0.67" spread="NA">NA=Not calculated on 1 participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.7</title>
        <description>Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds &amp; assessing twitch response at the adductor pollicis muscle. T1 &amp; T4 refer to the magnitudes (heights) of the first &amp; fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB.</description>
        <time_frame>From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.7 (ranging from ~0.4 minutes to ~20 minutes from sugammadex or placebo administration)</time_frame>
        <population>The PP population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo) &amp; had ≥1 post-baseline efficacy measurement for this outcome measure &amp; had no protocol violations. For efficacy, participants with incorrect randomization were included under the planned dose group.</population>
        <group_list>
          <group group_id="O1">
            <title>Infants: Placebo</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
          </group>
          <group group_id="O2">
            <title>Infants: Sugammadex 0.5 mg/kg</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O3">
            <title>Infants: Sugammadex 1 mg/kg</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O4">
            <title>Infants: Sugammadex 2 mg/kg</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O5">
            <title>Children: Placebo</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
          </group>
          <group group_id="O6">
            <title>Children: Sugammadex 0.5 mg/kg</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O7">
            <title>Children: Sugammadex 1 mg/kg</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered</description>
          </group>
          <group group_id="O8">
            <title>Children: Sugammadex 2 mg/kg</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O9">
            <title>Children: Sugammadex 4 mg/kg</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O10">
            <title>Adolescents: Placebo</title>
            <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
          </group>
          <group group_id="O11">
            <title>Adolescents: Sugammadex 0.5 mg/kg</title>
            <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O12">
            <title>Adolescents: Sugammadex 1 mg/kg</title>
            <description>Adolescents participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O13">
            <title>Adolescents: Sugammadex 2 mg/kg</title>
            <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O14">
            <title>Adolescents: Sugammadex 4 mg/kg</title>
            <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O15">
            <title>Adults: Placebo</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
          </group>
          <group group_id="O16">
            <title>Adults: Sugammadex 0.5 mg/kg</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O17">
            <title>Adults: Sugammadex 1 mg/kg</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O18">
            <title>Adults: Sugammadex 2 mg/kg</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O19">
            <title>Adults: Sugammadex 4 mg/kg</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O20">
            <title>Infants: Sugammadex 4 mg/kg</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.7</title>
          <description>Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds &amp; assessing twitch response at the adductor pollicis muscle. T1 &amp; T4 refer to the magnitudes (heights) of the first &amp; fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB.</description>
          <population>The PP population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo) &amp; had ≥1 post-baseline efficacy measurement for this outcome measure &amp; had no protocol violations. For efficacy, participants with incorrect randomization were included under the planned dose group.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="5"/>
                <count group_id="O17" value="5"/>
                <count group_id="O18" value="5"/>
                <count group_id="O19" value="5"/>
                <count group_id="O20" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.85" spread="8.65"/>
                    <measurement group_id="O2" value="2.47" spread="0.07"/>
                    <measurement group_id="O3" value="1.78" spread="0.18"/>
                    <measurement group_id="O4" value="0.58" spread="NA">NA=Not calculated on 1 participant</measurement>
                    <measurement group_id="O5" value="12.32" spread="7.00"/>
                    <measurement group_id="O6" value="2.62" spread="0.93"/>
                    <measurement group_id="O7" value="1.45" spread="0.38"/>
                    <measurement group_id="O8" value="0.75" spread="0.12"/>
                    <measurement group_id="O9" value="0.57" spread="0.13"/>
                    <measurement group_id="O10" value="18.62" spread="9.72"/>
                    <measurement group_id="O11" value="2.77" spread="1.27"/>
                    <measurement group_id="O12" value="1.07" spread="0.12"/>
                    <measurement group_id="O13" value="0.95" spread="0.30"/>
                    <measurement group_id="O14" value="0.83" spread="0.20"/>
                    <measurement group_id="O15" value="19.65" spread="5.38"/>
                    <measurement group_id="O16" value="1.62" spread="0.25"/>
                    <measurement group_id="O17" value="1.27" spread="0.35"/>
                    <measurement group_id="O18" value="0.87" spread="0.23"/>
                    <measurement group_id="O19" value="1.12" spread="0.38"/>
                    <measurement group_id="O20" value="0.42" spread="NA">NA=Not calculated on 1 participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.8</title>
        <description>Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds &amp; assessing twitch response at the adductor pollicis muscle. T1 &amp; T4 refer to the magnitudes (heights) of the first &amp; fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB.</description>
        <time_frame>From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.8 (ranging from ~0.5 minutes to ~25 minutes from sugammadex or placebo administration)</time_frame>
        <population>The PP population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo) &amp; had ≥1 post-baseline efficacy measurement for this outcome measure &amp; had no protocol violations. For efficacy, participants with incorrect randomization were included under the planned dose group.</population>
        <group_list>
          <group group_id="O1">
            <title>Infants: Placebo</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
          </group>
          <group group_id="O2">
            <title>Infants: Sugammadex 0.5 mg/kg</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O3">
            <title>Infants: Sugammadex 1 mg/kg</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O4">
            <title>Infants: Sugammadex 2 mg/kg</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O5">
            <title>Children: Placebo</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
          </group>
          <group group_id="O6">
            <title>Children: Sugammadex 0.5 mg/kg</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O7">
            <title>Children: Sugammadex 1 mg/kg</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered</description>
          </group>
          <group group_id="O8">
            <title>Children: Sugammadex 2 mg/kg</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O9">
            <title>Children: Sugammadex 4 mg/kg</title>
            <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O10">
            <title>Adolescents: Placebo</title>
            <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
          </group>
          <group group_id="O11">
            <title>Adolescents: Sugammadex 0.5 mg/kg</title>
            <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O12">
            <title>Adolescents: Sugammadex 1 mg/kg</title>
            <description>Adolescents participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O13">
            <title>Adolescents: Sugammadex 2 mg/kg</title>
            <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O14">
            <title>Adolescents: Sugammadex 4 mg/kg</title>
            <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O15">
            <title>Adults: Placebo</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
          </group>
          <group group_id="O16">
            <title>Adults: Sugammadex 0.5 mg/kg</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O17">
            <title>Adults: Sugammadex 1 mg/kg</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O18">
            <title>Adults: Sugammadex 2 mg/kg</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O19">
            <title>Adults: Sugammadex 4 mg/kg</title>
            <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
          </group>
          <group group_id="O20">
            <title>Infants: Sugammadex 4 mg/kg</title>
            <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.8</title>
          <description>Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds &amp; assessing twitch response at the adductor pollicis muscle. T1 &amp; T4 refer to the magnitudes (heights) of the first &amp; fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB.</description>
          <population>The PP population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo) &amp; had ≥1 post-baseline efficacy measurement for this outcome measure &amp; had no protocol violations. For efficacy, participants with incorrect randomization were included under the planned dose group.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="5"/>
                <count group_id="O17" value="5"/>
                <count group_id="O18" value="5"/>
                <count group_id="O19" value="5"/>
                <count group_id="O20" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.85" spread="10.42"/>
                    <measurement group_id="O2" value="2.97" spread="0.07"/>
                    <measurement group_id="O3" value="2.03" spread="0.17"/>
                    <measurement group_id="O4" value="0.58" spread="NA">NA=Not calculated on 1 participant</measurement>
                    <measurement group_id="O5" value="14.20" spread="8.32"/>
                    <measurement group_id="O6" value="3.42" spread="1.40"/>
                    <measurement group_id="O7" value="1.85" spread="0.70"/>
                    <measurement group_id="O8" value="0.95" spread="0.23"/>
                    <measurement group_id="O9" value="0.75" spread="0.45"/>
                    <measurement group_id="O10" value="21.92" spread="12.52"/>
                    <measurement group_id="O11" value="4.92" spread="4.08"/>
                    <measurement group_id="O12" value="1.35" spread="0.17"/>
                    <measurement group_id="O13" value="0.98" spread="0.38"/>
                    <measurement group_id="O14" value="0.87" spread="0.18"/>
                    <measurement group_id="O15" value="24.77" spread="9.33"/>
                    <measurement group_id="O16" value="2.22" spread="0.60"/>
                    <measurement group_id="O17" value="1.37" spread="0.35"/>
                    <measurement group_id="O18" value="1.07" spread="0.23"/>
                    <measurement group_id="O19" value="1.27" spread="0.30"/>
                    <measurement group_id="O20" value="0.67" spread="NA">NA=Not calculated on 1 participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through postoperative Day 7 (Up to 8 days)</time_frame>
      <desc>The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Infants: Placebo</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.</description>
        </group>
        <group group_id="E2">
          <title>Infants: Sugammadex .0.5 mg/kg</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E3">
          <title>Infants: Sugammadex 1 mg/kg</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E4">
          <title>Infants: Sugammadex 2 mg/kg</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E5">
          <title>Infants: Sugammadex 4 mg/kg</title>
          <description>Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E6">
          <title>Children: Placebo</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered</description>
        </group>
        <group group_id="E7">
          <title>Children: Sugammadex 0.5 mg/kg</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E8">
          <title>Children: Sugammadex 1 mg/kg</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E9">
          <title>Children: Sugammadex 2 mg/kg</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E10">
          <title>Children: Sugammadex 4 mg/kg</title>
          <description>Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E11">
          <title>Adolescents: Placebo</title>
          <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered</description>
        </group>
        <group group_id="E12">
          <title>Adolescents: Sugammadex 0.5 mg/kg</title>
          <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E13">
          <title>Adolescents: Sugammadex 1 mg/kg</title>
          <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E14">
          <title>Adolescents: Sugammadex 2 mg/kg</title>
          <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E15">
          <title>Adolescents: Sugammadex 4 mg/kg</title>
          <description>Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E16">
          <title>Adults: Placebo</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered</description>
        </group>
        <group group_id="E17">
          <title>Adults: Sugammadex 0.5 mg/kg</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E18">
          <title>Adults: Sugammadex 1 mg/kg</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E19">
          <title>Adults: Sugammadex 2 mg/kg</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.</description>
        </group>
        <group group_id="E20">
          <title>Adults: Sugammadex 4 mg/kg</title>
          <description>Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E19" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E20" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" events="6" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E15" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haematuria traumatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E15" events="5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperkinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Excitability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Organon recognizes the right of the investigator(s) to publish, but all publications must be based on data validated by Organon. Any such scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to Organon, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

